Recruiting
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NCT06243354
- Conditions
- Efficacy, Safety, Tolerability
- Locations
-
- Fujian Provincial Cancer Hospital Fuzhou, Fujian, China
- Hunan Provincial Cancer Hospital Changsha, Hunan, China
- The first Hospital of China Medical University Shenyang, Liaoning, China
- Shandong Provincial Cancer Hospital Jinan, Shandong, China